CRISPR Therapeutics AG: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in CRISPR Therapeutics AG via a Schedule 13G filing with the SEC (accession 0000093751-26-000637). The filing signals that the institutional investor has crossed the 5% beneficial ownership threshold in the gene-editing company. The exact share count and percentage were not specified in the headline disclosure. The move matters because 13G filings are closely watched for signals of passive institutional conviction in biotech names. What to watch next: the full filing details on share count and any subsequent 13G/A amendments that reveal whether State Street adds to or trims the position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
CRISPR Therapeutics AG, State Street Corp